
Beneficient (NASDAQ:BENF – Free Report) – Stock analysts at Sidoti Csr increased their Q2 2026 earnings per share estimates for Beneficient in a research report issued on Wednesday, November 12th. Sidoti Csr analyst B. Mccarthy now anticipates that the company will post earnings per share of ($0.31) for the quarter, up from their previous forecast of ($0.32). The consensus estimate for Beneficient’s current full-year earnings is ($2.29) per share. Sidoti Csr also issued estimates for Beneficient’s Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($1.67) EPS, Q1 2027 earnings at ($0.28) EPS, Q2 2027 earnings at ($0.18) EPS, Q3 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.42) EPS.
BENF has been the subject of a number of other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Beneficient in a research report on Tuesday, November 11th. Wall Street Zen raised shares of Beneficient to a “sell” rating in a report on Saturday, November 1st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.
Beneficient Price Performance
Shares of NASDAQ BENF opened at $0.51 on Monday. Beneficient has a 52-week low of $0.22 and a 52-week high of $2.36. The business has a fifty day moving average of $0.59 and a two-hundred day moving average of $0.42.
Beneficient Company Profile
Beneficient, a technology-enabled financial services company, provides liquidity solutions and related trustee, custody and trust administrative services to participants in the alternative asset industry in the United States. It operates through Ben Liquidity, Ben Custody, and Customer ExAlt Trusts segments.
Featured Stories
- Five stocks we like better than Beneficient
- How to Calculate Return on Investment (ROI)
- 4 Cold-Weather Stocks to Buy as Winter Spending Heats Up
- Technology Stocks Explained: Here’s What to Know About Tech
- Disney Stock Drops—Will Earnings Pave Way for a YouTube TV Truce?
- How to trade using analyst ratings
- Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?
Receive News & Ratings for Beneficient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beneficient and related companies with MarketBeat.com's FREE daily email newsletter.
